Cargando…

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes

BACKGROUND: Pharmacogenetics contributes to inter-individual variability in pharmacokinetics (PK) of efavirenz (EFV), leading to variations in both efficacy and toxicity. The purpose of this study was to assess the effect of genetic factors on EFV pharmacokinetics, treatment outcomes and genotype ba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mukonzo, Jackson K., Owen, Joel S., Ogwal-Okeng, Jasper, Kuteesa, Ronald B., Nanzigu, Sarah, Sewankambo, Nelson, Thabane, Lehana, Gustafsson, Lars L., Ross, Colin, Aklillu, Eleni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3909010/ https://www.ncbi.nlm.nih.gov/pubmed/24497997 http://dx.doi.org/10.1371/journal.pone.0086919

Ejemplares similares

Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study
por: Mukonzo, Jackson K, et al.
Publicado: (2013)

Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients
por: Ahmed, Jemal Hussien, et al.
Publicado: (2020)

Predictors of Efavirenz Plasma Exposure, Auto-Induction Profile, and Effect of Pharmacogenetic Variations among HIV-Infected Children in Ethiopia: A Prospective Cohort Study
por: Chala, Adugna, et al.
Publicado: (2021)

Effect of Efavirenz on Endogenous Progesterone Concentrations and Contraceptive Outcomes among Ugandan HIV Infected Women Coadministering Ethinylestradiol/Levonorgestrel
por: Munkwase, Grant, et al.
Publicado: (2017)

Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination
por: Ntale, Muhammad, et al.
Publicado: (2009)

Constitutive androstane receptor and pregnane X receptor genotype influence efavirenz plasma concentration and CYP2B6 enzyme activity
por: Petros, Zelalem, et al.
Publicado: (2022)

Impact of Population and Pharmacogenetics Variations on Efavirenz Pharmacokinetics and Immunologic Outcomes During Anti-Tuberculosis Co-Therapy: A Parallel Prospective Cohort Study in Two Sub-Sahara African Populations
por: Mugusi, Sabina, et al.
Publicado: (2020)

Pharmacogenetic & Pharmacokinetic Biomarker for Efavirenz Based ARV and Rifampicin Based Anti-TB Drug Induced Liver Injury in TB-HIV Infected Patients
por: Yimer, Getnet, et al.
Publicado: (2011)

CYP3A and CYP2B6 Genotype Predicts Glucose Metabolism Disorder among HIV Patients on Long-Term Efavirenz-Based ART: A Case-Control Study
por: Tadesse, Wondmagegn Tamiru, et al.
Publicado: (2022)

Early or deferred initiation of efavirenz during rifampicin‐based TB therapy has no significant effect on CYP3A induction in TB‐HIV infected patients
por: Aklillu, Eleni, et al.
Publicado: (2020)

Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6*6 genotype
por: Kitabi, Eliford Ngaimisi, et al.
Publicado: (2018)

Associations between efavirenz concentrations, pharmacogenetics and neurocognitive performance in people living with HIV in Nigeria
por: Nwogu, Jacinta N., et al.
Publicado: (2021)

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants
por: Mollan, Katie R, et al.
Publicado: (2017)

Phytochemical Analysis, Acute Toxicity, as well as Antihyperglycemic and Antidiabetic Activities of Corchorus olitorius L. Leaf Extracts
por: Nakaziba, Rebecca, et al.
Publicado: (2022)

Neuropsychiatric manifestations among HIV-1 infected African patients receiving efavirenz-based cART with or without tuberculosis treatment containing rifampicin
por: Mugusi, Sabina, et al.
Publicado: (2018)

Factors predicting home storage of medicines in Northern Uganda
por: Ocan, Moses, et al.
Publicado: (2014)

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children
por: Bienczak, Andrzej, et al.
Publicado: (2016)

Prevalence of K13-propeller gene polymorphisms among Plasmodium falciparum parasites isolated from adult symptomatic patients in northern Uganda
por: Ocan, Moses, et al.
Publicado: (2016)

Potential drug–drug interactions between antiretroviral therapy and treatment regimens for multi-drug resistant tuberculosis: Implications for HIV care of MDR-TB co-infected individuals
por: Mukonzo, Jackson, et al.
Publicado: (2019)

Mentoring in biostatistics: some suggestions for reform
por: Odueyungbo, Adefowope, et al.
Publicado: (2012)

Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
por: Zhang, Y, et al.
Publicado: (2010)

Pharmacogenetic interactions of efavirenz or rifampin and isoniazid with levonorgestrel emergency contraception during treatment of HIV or tuberculosis
por: Agyemang, Nana, et al.
Publicado: (2023)

An Expanded Analysis of Pharmacogenetics Determinants of Efavirenz Response that Includes 3′-UTR Single Nucleotide Polymorphisms among Black South African HIV/AIDS Patients
por: Swart, Marelize, et al.
Publicado: (2016)

Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
por: Shah, Manish B., et al.
Publicado: (2018)

CYP46A1-dependent and independent effects of efavirenz treatment
por: Mast, Natalia, et al.
Publicado: (2020)

Importance of Ethnicity, CYP2B6 and ABCB1 Genotype for Efavirenz Pharmacokinetics and Treatment Outcomes: A Parallel-Group Prospective Cohort Study in Two Sub-Saharan Africa Populations
por: Ngaimisi, Eliford, et al.
Publicado: (2013)

The influence of nevirapine and efavirenz-based anti-retroviral therapy on the pharmacokinetics of lumefantrine and anti-malarial dose recommendation in HIV-malaria co-treatment
por: Maganda, Betty A, et al.
Publicado: (2015)

Availability and utilization of the WHO recommended priority lifesaving medicines for under five-year old children in public health facilities in Uganda: a cross-sectional survey
por: Nsabagasani, Xavier, et al.
Publicado: (2015)

Prevalence and predictors of prior antibacterial use among patients presenting to hospitals in Northern Uganda
por: Ocan, Moses, et al.
Publicado: (2015)

Pharmacogenetics of CYP2A6, CYP2B6, and UGT2B7 in the Context of HIV Treatments in African Populations
por: Ford, Graeme R., et al.
Publicado: (2022)

Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin
por: Soeria-Atmadja, Sandra, et al.
Publicado: (2017)

Prevalence and risk factors for efavirenz-based antiretroviral treatment–associated severe vitamin D deficiency: A prospective cohort study
por: Nylén, Hanna, et al.
Publicado: (2016)

Patterns and Predictors of Self-Medication in Northern Uganda
por: Ocan, Moses, et al.
Publicado: (2014)

Explaining the slow transition of child-appropriate dosage formulations from the global to national level in the context of Uganda: a qualitative study
por: Nsabagasani, Xavier, et al.
Publicado: (2015)

Genetic and non‐genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus‐1‐infected children in Ethiopia
por: Chala, Adugna, et al.
Publicado: (2023)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020)

Household antimicrobial self-medication: a systematic review and meta-analysis of the burden, risk factors and outcomes in developing countries
por: Ocan, Moses, et al.
Publicado: (2015)

The “child size medicines” concept: policy provisions in Uganda
por: Nsabagasani, Xavier, et al.
Publicado: (2015)

Antimicrobial Bioactivity and GC-MS Analysis of Different Extracts of Corchorus olitorius L Leaves
por: Nakaziba, Rebecca, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iogmaim5a9clcerpvoa8m1peb6